Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Posted in: Drug Trial News | Medical Condition News
Tags: Anemia, Angioedema, Anorexia, Anti-Inflammatory, Arthralgia, Back Pain, Basal Cell Carcinoma, Birth Control, birth defects, Blood Donation, Cancer, Carcinoma, Cell, Chronic Lymphocytic Leukemia, Chronic Obstructive Pulmonary Disease,…
Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: